Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-10-20 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : L’autorisation de Sanofi pour Tzield a été acceptée aux États-Unis pour le diabète de type 1 de stade 3 dans le cadre du programme pilote du voucher national de priorité du Comm
Regulatory Filings Classification · 100% confidence The document is a press release from Sanofi announcing that the FDA has accepted a supplemental Biologics License Application (sBLA) for their drug Tzield for priority review. It details the clinical trial background (PROTECT study), the regulatory status, and provides contact information for investor relations and media. As it is a corporate announcement regarding regulatory progress and product development, it falls under the category of general regulatory announcements/filings.
2025-10-20 French
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Regulatory Filings Classification · 100% confidence The document is a press release from Sanofi announcing that the US FDA has accepted a supplemental biologics license application (sBLA) for expedited review of their drug 'Tzield'. It details the clinical study background, the regulatory pathway, and provides contact information for media and investor relations. As this is a general regulatory announcement regarding product development and FDA status that does not fit into specific financial reporting categories like 10-K or Earnings Release, it is classified as a Regulatory Filing (RNS).
2025-10-20 English
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Regulatory Filings Classification · 95% confidence The document is a press release detailing clinical trial results (ALPHAMEDIX-02 phase 2 study) presented at the ESMO Congress. It focuses on medical efficacy, safety data, and strategic development of a specific drug (AlphaMedix). This type of document, which provides updates on company research and development progress, is classified as a Regulatory Filing (RNS) as it does not fit into specific financial reporting categories like 10-K or Earnings Release, and it is not a standalone investor presentation or legal proceeding.
2025-10-20 English
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées con
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical trial results (Phase 2) for a drug candidate (AlphaMedix) presented at the ESMO 2025 conference. It details efficacy data, patient cohorts, and clinical trial identifiers. As it is a corporate announcement regarding research and development progress rather than a formal financial report, a regulatory filing, or a shareholder meeting document, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-10-20 French
Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the results of a clinical study (FLUNITY-HD) regarding their high-dose flu vaccine. It details clinical trial outcomes, provides quotes from researchers, and includes standard corporate boilerplate, contact information, and forward-looking statements. It does not constitute a formal financial report (10-K, IR), a regulatory filing, or a specific shareholder notice. As it is a general corporate announcement regarding product efficacy and research, it falls under the category of general regulatory announcements/press releases.
2025-10-20 French
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Earnings Release Classification · 95% confidence The document is a corporate press release from Sanofi announcing the results of a clinical study (FLUNITY-HD) regarding their influenza vaccine. It does not fit into specific financial reporting categories like 10-K, IR, or ER, as it focuses on medical research outcomes rather than quarterly financial results or regulatory filings. Since it is a general corporate announcement regarding company activities and research, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements. Q4 2025
2025-10-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.